Drug Approval
Name: Pyrukynd
Indications: To treat hemolytic anemia in pyruvate kinase deficiency.
Active Ingredient: Mitapivat
Company: Agios Pharmaceuticals Inc
Approval Date: 2/17/2022
Learn more: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-pyrukynd